Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its ...

The company’s stock rise reflects investor optimism following the news that Hims & Hers will provide both branded versions of ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Eli ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.

Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Mitsubishi UFJ Asset Management upped its stake in Eli Lilly by 11.8%, adding 137,287 shares in Q4. The firm now holds ...

Nvidia’s momentum has been weighed down by cooling AI hype and broader market instability. Despite reporting blockbuster Q4 ...

While tariffs have triggered market volatility, certain pharmaceutical stocks still present strong investment opportunities.